Clinical Trials
Callisto is developing a portfolio of novel therapeutics through a set of clinical trials. At present we have 3 active clinical trials:
| Compound |
Callisto Protocol and Synergy Pharmaceuticals |
Phase |
Description |
Status |
| Atiprimod |
CP-106 |
2 |
Open-Label Study of Atiprimod Treatment for Patients with Neuroendocrine Carcinoma. |
Enrollment complete |
| CP-AT202-07 |
2 |
Extension of trial protocol CP-106 for patients who completed this study. |
Enrollment limited to CP-106 trial participants |
| CP-101 |
1/2a |
Open-Label Study of Atiprimod Treatment for Patients with Refractory or Relapsed Multiple Myeloma. |
Enrollment complete |
| L-Annamycin |
CP-103 |
1/2a |
Study of L-Annamycin in Patients with Refractory or Relapsed Acute Lymphocytic Leukemia. |
Enrolling |
| CP-105 |
1 |
Study of Liposomal Annamycin in pediatric leukemia |
Enrolling |
